ABSTRACT

Obesity has become increasingly prevalent and is responsible for numerous other conditions like type 2 diabetes, hypertension, and cancer, contributing to a significant burden of disease. According to guidelines, managing obesity demands a multifaceted strategy that includes initiation of a comprehensive lifestyle intervention program and pharmacotherapy.  Currently, evidence has emerged of a new era of pharmacotherapy to support weight management, one of which is liraglutide. Liraglutide is a GLP-1 RA that has been proven to be effective effective for weight loss in both diabetic and non-diabetic patients. Apart from reducing body weight, liraglutide was also found to be useful in reducing HbA1c levels in diabetic patients. Currently,  liraglutide therapy for obesity is advised to be administered at a dose of 3 mg, with a gradual titration. The most common side effects are related to the gastrointestinal system such as nausea and vomiting.

Keywords: Liraglutide, Obesity, Overweight, Diabetes, Non-diabetes

ABSTRAK

 Prevalensi obesitas telah meningkat pesat dan berhubungan dengan banyak penyakit lainnya seperti T2DM, hipertensi hingga kanker sehingga menimbulkan beban penyakit yang tinggi. Pedoman merekomendasikan pendekatan multifaktorial untuk tatalaksana obesitas, mencakup inisiasi program intervensi gaya hidup yang komprehensif dan farmakoterapi.  Saat ini telah muncul bukti era baru farmakoterapi untuk mendukung pengelolaan berat badan, salah satunya adalah liraglutide. Liraglutide adalah GLP-1 RA yang telah ditemukan efektif untuk menurunkan berat badan pada pasien diabetik dan non-diabetik. Selain menurunkan berat badan, liraglutide juga ditemukan bermanfaat dalam menurunkan kadar HbA1c pada pasien diabetik. Saat ini, penggunaan liraglutide direkomendasikan pada dosis 3 mg untuk terapi obesitas, dengan cara pemberian dititrasi perlahan. Efek samping yang paling umum terjadi yaitu terkait dengan sistem gastrointestinal seperti mual dan muntah.  

Kata Kunci: Liraglutide, Obesitas, Overweight, Diabetes, Non-Diabetes

Alruwaili, H., Dehestani, B., & le Roux, C. W. (2021). Clinical Impact of Liraglutide as a Treatment of Obesity. Clinical Pharmacology: Advances and Applications, Volume 13, 53–60. https://doi.org/10.2147/CPAA.S276085

Anderson, J., Kushner, R., Miller, E., Nadglowski, J., & Still, C. (2023). Overweight and Obesity Management for Primary Care Clinicians: Executive Summary. Clinical Diabetes, 41(1), 85–89. https://doi.org/10.2337/cd22-0082

Baker, J. S., Supriya, R., Dutheil, F., & Gao, Y. (2022). Obesity: Treatments, Conceptualizations, and Future Directions for a Growing Problem. Biology, 11(2), 160. https://doi.org/10.3390/biology11020160

Collins, L., & Costello, R. A. (2023). Glucagon-Like Peptide-1 Receptor Agonists. In StatPearls. http://www.ncbi.nlm.nih.gov/pubmed/31641522

Cornejo-Estrada, A., Nieto-Rodríguez, C., León-Figueroa, D. A., Moreno-Ramos, E., Cabanillas-Ramirez, C., & Barboza, J. J. (2023). Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Children, 10(2), 208. https://doi.org/10.3390/children10020208

Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022). Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Therapeutic Advances in Chronic Disease, 13, 204062232211080. https://doi.org/10.1177/20406223221108064

Destra, E., Anggraeni, N., Firmansyah, Y., & Santoso, A. H. (2023). Waist to hip ratio in Cardiovascular Disease Risk : A Review of the Literature. MAHESA : Malahayati Health Student Journal, 3(6), 1770–1781. https://doi.org/10.33024/mahesa.v3i6.10595

Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010). Liraglutide. Nature Reviews Drug Discovery, 9(4), 267–268. https://doi.org/10.1038/nrd3148

Durrer Schutz, D., Busetto, L., Dicker, D., Farpour-Lambert, N., Pryke, R., Toplak, H., Widmer, D., Yumuk, V., & Schutz, Y. (2019). European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obesity Facts, 12(1), 40–66. https://doi.org/10.1159/000496183

Elkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J., & Bellanger, D. (2022). Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and Sterility, 118(2), 371–381. https://doi.org/10.1016/j.fertnstert.2022.04.027

Gadde, K. M., Martin, C. K., Berthoud, H.-R., & Heymsfield, S. B. (2018). Obesity. Journal of the American College of Cardiology, 71(1), 69–84. https://doi.org/10.1016/j.jacc.2017.11.011

Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020). Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care, 43(5), 1085–1093. https://doi.org/10.2337/dc19-1745

Ghanim, H., Batra, M., Green, K., Abuaysheh, S., Hejna, J., Makdissi, A., Borowski, R., Kuhadiya, N. D., Chaudhuri, A., & Dandona, P. (2020). Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26‐week randomized controlled trial; mechanisms of weight loss. Diabetes, Obesity and Metabolism, 22(10), 1742–1752. https://doi.org/10.1111/dom.14090

Holly, J. M. P., Biernacka, K., & Perks, C. M. (2019). Systemic Metabolism, Its Regulators, and Cancer: Past Mistakes and Future Potential. Frontiers in Endocrinology, 10, 65. https://doi.org/10.3389/fendo.2019.00065

Holst, J. J. (2007). The Physiology of Glucagon-like Peptide 1. Physiological Reviews, 87(4), 1409–1439. https://doi.org/10.1152/physrev.00034.2006

Janez, M., Rizzo, M., Haluzík, M., & Janež, A. (2022). Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Advances in Therapy, 39(6), 2452–2467. https://doi.org/10.1007/s12325-022-02153-x

Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 10. https://doi.org/10.3389/fendo.2019.00155

Ladenheim, E. (2015). Liraglutide and obesity: a review of the data so far. Drug Design, Development and Therapy, 1867. https://doi.org/10.2147/DDDT.S58459

Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 384(18), 1719–1730. https://doi.org/10.1056/NEJMoa2028198

Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice, 3(1), 3–14. https://doi.org/10.1002/osp4.84

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021). A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. Medicina, 57(7), 669. https://doi.org/10.3390/medicina57070669

Timothy Garvey, W. (2019). The diagnosis and evaluation of patients with obesity. Current Opinion in Endocrine and Metabolic Research, 4, 50–57. https://doi.org/10.1016/j.coemr.2018.10.001

Trenson, L., Trenson, S., van Nes, F., Moyson, C., Lannoo, M., Deleus, E., Meulemans, A., Matthys, C., Mertens, A., Van der Schueren, B., & Vangoitsenhoven, R. (2022). Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. Obesity Facts, 15(1), 83–89. https://doi.org/10.1159/000520217

Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021). GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 12, 204201882199732. https://doi.org/10.1177/2042018821997320